Use of a HIV derived accessory protein for the reactivation of latent HIV
The present invention concerns the use of a protein comprising at least a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof for the reactivation of latent human immunodeficiency virus (HIV) from cells present in a HIV-infected patient.
1 .- 9 . (canceled)
10 . An isolated protein having the amino acid sequence of the group consisting of: SEQ ID. NO: 1, SEQ ID. NO: 2 and SEQ ID. NO: 3.
11 . An isolated protein of claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 1.
12 . An isolated protein of claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 2.
13 . An isolated protein of claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 3.
14 . A pharmaceutical composition, comprising the protein of claim 10 .
15 . A pharmaceutical composition of claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 1.
16 . A pharmaceutical composition of claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 2.
17 . A pharmaceutical composition of claim 10 , wherein the protein has the amino acid sequence of SEQ ID. NO: 3.
18 . A method for treating a subject with human immunodeficiency virus (HIV) comprising the steps of:
a) administering to said subject an effective amount of the composition of claim 14 ; and
b) administering to said subject an effective amount of one or more anti-viral agent.
19 . A method of treating a subject of claim 18 , wherein the subject is administered an effective amount of the composition of claim 15 .
20 . A method of treating a subject of claim 18 , wherein the subject is administered an effective amount of the composition of claim 16 .
21 . A method of treating a subject of claim 18 , wherein the subject is administered an effective amount of the composition of claim 17 .